Difference between revisions of "Prostate cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (formatting of headers)
(Added regimens)
Line 5: Line 5:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
  
−
=Metastatic castrate-resistant disease=
+
=Androgen deprivation therapy (ADT) & radiation therapy=
 +
==Adjuvant Goserelin (Zoladex) & RT==
 +
===Regimen===
 +
*[[Goserelin (Zoladex)]] 3.6 mg SC every 4 weeks, to start during the last week of radiation therapy and to continue indefinitely or until progression
 +
*Radiation therapy, 1.8-2 Gy per fraction, with an initial 44-46 Gy to the pelvis, then an additional boost to the prostate that resulted in a total dose of 65-70 Gy in definitive radiation patients; 60-65 Gy total dose for post-prostatectomy patients
 +
 
 +
===References===
 +
# Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90. [http://www.sciencedirect.com/science/article/pii/S036030160402468X link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15817329 PubMed]
 +
 
 +
==Goserelin (Zoladex), Flutamide (Eulexin), RT==
 +
===Regimen===
 +
*[[Goserelin (Zoladex)]] 3.6 mg SC every 4 weeks, to start 2 months prior to radiation therapy and to continue at least through the end of radiation therapy
 +
*[[Flutamide (Eulexin)]] 250 mg PO three times per day, to start 2 months prior to radiation therapy and to continue at least through the end of radiation therapy
 +
*Radiation therapy is started 2 months after start of androgen deprivation therapy (ADT), 1.8-2 Gy per fraction, with an initial 44-46 Gy to the pelvis, then an additional conedown to the prostate that resulted in a total dose of 65-70 Gy
 +
*Long-term ADT may continue to be given for up to 24 months after the completion of radiation therapy
 +
 
 +
===References===
 +
# Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52. [http://www.sciencedirect.com/science/article/pii/S0360301601015796 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11483335 PubMed]
 +
# Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-91. Epub 2008 Jan 2. [http://jco.ascopubs.org/content/26/4/585.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18172188 PubMed]
 +
# D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23;299(3):289-95. [http://jama.ama-assn.org/content/299/3/289.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18212313 PubMed]
 +
# Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/15/2497.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18413638 PubMed]
 +
# Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18. [http://www.nejm.org/doi/full/10.1056/NEJMoa1012348 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21751904 PubMed]
 +
 
 +
==Leuprolide (Lupron), Flutamide (Eulexin), RT==
 +
===Regimen===
 +
*[[Leuprolide (Lupron)]] 7.5 mg SC every 4 weeks x 4 months, to start 2 months prior to radiation therapy
 +
*[[Flutamide (Eulexin)]] 250 mg PO three times per day x 4 months, to start 2 months prior to radiation therapy
 +
*Radiation therapy is started 2 months after start of androgen deprivation therapy (ADT), 1.8-2 Gy per fraction, with an initial 44-46 Gy to the pelvis, then an additional conedown to the prostate that resulted in a total dose of 65-70 Gy
 +
 
 +
===References===
 +
# Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18. [http://www.nejm.org/doi/full/10.1056/NEJMoa1012348 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21751904 PubMed]
 +
 
 +
=Hormonal therapy=
 +
==Bicalutamide (Casodex)==
 +
===Regimen===
 +
''Not approved for monotherapy in the United States.  See combination regimens with Goserelin (Zoladex) & Leuprolide (Lupron).''
 +
*[[Bicalutamide (Casodex)]] 150 mg PO daily
 +
 
 +
===References===
 +
# Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447-56. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/9643663 PubMed]
 +
# Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579-82. [http://www.sciencedirect.com/science/article/pii/S0022534705670322 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11025708 PubMed]
 +
 
 +
==Degarelix (Firmagon)==
 +
===Regimen===
 +
*[[Degarelix (Firmagon)]] 240 mg (given as 2 x 120 mg injections) SC once as an initial dose
 +
**Then, starting 28 days later, [[Degarelix (Firmagon)]] 80-160 mg (80 mg is recommended dose in package insert) SC every 28 days
 +
 
 +
===References===
 +
# Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. [http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19035858 PubMed]
 +
# [http://www.firmagon.us/docs/fpi-physician.pdf Degarelix (Firmagon) package insert]
 +
# Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836-42. Epub 2009 Nov 20. [http://www.europeanurology.com/article/S0302-2838%2809%2901171-3 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19962227 PubMed]
 +
 
 +
==Flutamide (Eulexin)==
 +
===Regimen===
 +
''Not approved for monotherapy in the United States.  See combination regimens with Goserelin (Zoladex) & Leuprolide (Lupron).''
 +
*[[Flutamide (Eulexin)]] 250 mg PO three times per day
 +
 
 +
===References===
 +
# Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119-29; discussion 129-30. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8367920 PubMed]
 +
# Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 1997;32(4):391-5; discussion 395-6. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/9412794 PubMed]
 +
 
 +
==Goserelin (Zoladex)==
 +
===Regimen===
 +
*[[Goserelin (Zoladex)]] 3.6 mg SC every 4 weeks
 +
 
 +
===References===
 +
# Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502-8. [http://www.ncbi.nlm.nih.gov/pubmed/1828183 PubMed]
 +
# Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119-29; discussion 129-30. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8367920 PubMed]
 +
# Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ, Kennealey GT. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995 Aug;46(2):220-6. [http://www.sciencedirect.com/science/article/pii/S0090429599801976 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7624991 PubMed]
 +
# Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579-82. [http://www.sciencedirect.com/science/article/pii/S0022534705670322 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11025708 PubMed]
 +
 
 +
==Goserelin (Zoladex) & Bicalutamide (Casodex)==
 +
===Regimen===
 +
*[[Goserelin (Zoladex)]] 3.6 mg SC every 4 weeks
 +
*[[Bicalutamide (Casodex)]] 50 mg PO daily
 +
 
 +
===References===
 +
# Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
 +
# Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
 +
 
 +
==Goserelin (Zoladex) & Flutamide (Eulexin)==
 +
===Regimen===
 +
*[[Goserelin (Zoladex)]] 3.6 mg SC every 4 weeks
 +
*[[Flutamide (Eulexin)]] 250 mg PO three times per day
 +
 
 +
===References===
 +
# Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119-29; discussion 129-30. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8367920 PubMed]
 +
# Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
 +
# Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
 +
 
 +
==Leuprolide (Lupron)==
 +
===Regimen===
 +
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 3-month depot]] 22.5 mg IM every 12 weeks
 +
OR
 +
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM every 4 weeks
 +
 
 +
Supportive medications (varies depending on reference):
 +
*[[Bicalutamide (Casodex)]] 50 mg PO daily for protection from testosterone flare
 +
 
 +
===References===
 +
# Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996 Jul-Aug;18(4):647-57. [http://www.sciencedirect.com/science/article/pii/S0149291896802153 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8879893 PubMed]
 +
# Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. [http://jco.ascopubs.org/content/25/12/1596.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/17404365 PubMed]
 +
# Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. [http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19035858 PubMed]
 +
# Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836-42. Epub 2009 Nov 20. [http://www.europeanurology.com/article/S0302-2838%2809%2901171-3 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19962227 PubMed]
 +
 
 +
==Leuprolide (Lupron) & Bicalutamide (Casodex)==
 +
===Regimen===
 +
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM every 4 weeks
 +
*[[Bicalutamide (Casodex)]] 50 mg PO daily
 +
 
 +
===References===
 +
# Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
 +
# Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
 +
 
 +
==Leuprolide (Lupron) & Flutamide (Eulexin)==
 +
===Regimen===
 +
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM every 4 weeks
 +
*[[Flutamide (Eulexin)]] 250 mg PO three times per day
 +
 
 +
===References===
 +
# Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
 +
# Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
 +
 
 +
==Nilutamide (Nilandron)==
 +
===Regimen===
 +
''Approved "for use in combination with surgical castration for the treatment of metastatic prostate cancer."''
 +
*[[Nilutamide (Nilandron)]] 300 mg PO daily x 1 month, then 150 mg PO daily
 +
 
 +
'''start the day of, or day after surgical castration/orchiectomy'''
 +
 
 +
===References===
 +
# Janknegt RA. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Cancer. 1993 Dec 15;72(12 Suppl):3874-7. [http://www.ncbi.nlm.nih.gov/pubmed/8252507 PubMed]
 +
# Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol. 1997 Jul;158(1):160-3. [http://www.ncbi.nlm.nih.gov/pubmed/9186345 PubMed]
 +
# de Reijke T, Derobert E; Anandron /Nilutamide Study Group. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol. 2002 Aug;42(2):139-46. [http://www.europeanurology.com/article/S0302-2838%2802%2900272-5 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12160584 PubMed]
 +
# [http://products.sanofi.us/nilandron/nilandron.pdf Nilutamide (Nilandron) package insert]
 +
 
 +
=Second-line hormonal therapy=
 +
==Abiraterone (Zytiga)==
 +
===Regimen===
 +
*[[Abiraterone (Zytiga)]] 1000 mg PO daily, 1 hour before or 2 hours after meals
 +
*[[Prednisone (Sterapred)]] 5 mg PO BID
 +
 
 +
===References===
 +
# de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. [http://www.nejm.org/doi/full/10.1056/NEJMoa1014618 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21612468 PubMed]
 +
 
 +
==Ketoconazole (Nizoral) & Hydrocortisone==
 +
===Regimen===
 +
*[[Ketoconazole (Nizoral)]] 400 mg PO three times per day
 +
*Hydrocortisone 30 mg PO QAM, 10 mg PO QPM
 +
 
 +
===References===
 +
# Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15;22(6):1025-33. [http://jco.ascopubs.org/content/22/6/1025.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15020604 PubMed]
 +
 
 +
==Ketoconazole (Nizoral), Hydrocortisone, Dutasteride (Avodart)==
 +
===Regimen===
 +
*[[Ketoconazole (Nizoral)]] 400 mg PO three times per day
 +
*Hydrocortisone 30 mg PO QAM, 10 mg PO QPM
 +
*[[Dutasteride (Avodart)]] 0.5 mg PO daily
 +
 
 +
===References===
 +
# Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15;15(22):7099-105. Epub 2009 Nov 3. [http://clincancerres.aacrjournals.org/content/15/22/7099.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19887483 PubMed]
 +
 
 +
=Chemotherapy for metastatic castrate-resistant disease=
 
==Cabazitaxel (Jevtana)==
 
==Cabazitaxel (Jevtana)==
 
===Regimen===
 
===Regimen===
 
*[[Cabazitaxel (Jevtana)]] 25 mg/m2 IV over 1 hour on day 1
 
*[[Cabazitaxel (Jevtana)]] 25 mg/m2 IV over 1 hour on day 1
−
*[[Prednisone (Sterapred)]] 10 mg PO on days 1-21
+
*[[Prednisone (Sterapred)]] 10 mg PO daily on days 1-21
  
 
'''21-day cycles x up to 10 cycles'''
 
'''21-day cycles x up to 10 cycles'''
Line 17: Line 179:
  
 
===References===
 
===References===
−
# de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed]
+
# de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed]
 +
 
 +
==Docetaxel (Taxotere)==
 +
===Regimen #1, Tannock, et al. 2004 & Berthold, et al. 2008===
 +
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 1 hour on day 1
 +
*[[Prednisone (Sterapred)]] 5 mg PO BID on days 1-21
 +
 
 +
'''21-day cycles x up to 10 cycles'''
 +
 
 +
Supportive medications:
 +
*[[Dexamethasone (Decadron)]] 8 mg PO/IV given 12 hours, 3 hours, and 1 hour before docetaxel
 +
*Antiemetics "according to local practice"
 +
 
 +
===Regimen #2, weekly schedule, Tannock, et al. 2004 & Berthold, et al. 2008===
 +
*[[Docetaxel (Taxotere)]] 30 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, 29
 +
*[[Prednisone (Sterapred)]] 5 mg PO BID on days 1-21
 +
 
 +
'''42-day cycles x up to 5 cycles'''
 +
 
 +
Supportive medications:
 +
*[[Dexamethasone (Decadron)]] 8 mg PO/IV 1 hour before docetaxel
 +
*Antiemetics "according to local practice"
 +
 
 +
===References===
 +
# Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. [http://www.nejm.org/doi/full/10.1056/NEJMoa040720 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15470213 PubMed]
 +
# Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242-5. [http://jco.ascopubs.org/content/26/2/242.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18182665 PubMed]
  
 
==Mitoxantrone (Novantrone)==
 
==Mitoxantrone (Novantrone)==
 
===Regimen===
 
===Regimen===
 
*[[Mitoxantrone (Novantrone)]] 12 mg/m2 IV over 15-30 minutes on day 1
 
*[[Mitoxantrone (Novantrone)]] 12 mg/m2 IV over 15-30 minutes on day 1
−
*[[Prednisone (Sterapred)]] 10 mg PO on days 1-21
+
*[[Prednisone (Sterapred)]] 10 mg PO daily (or 5 mg PO BID) on days 1-21
  
 
'''21-day cycles x up to 10 cycles'''
 
'''21-day cycles x up to 10 cycles'''
  
 
===References===
 
===References===
−
# de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed]
+
# Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. [http://www.nejm.org/doi/full/10.1056/NEJMoa040720 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15470213 PubMed]
 +
# Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242-5. [http://jco.ascopubs.org/content/26/2/242.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18182665 PubMed]
 +
# de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed]
 +
 
 +
=Immunotherapy for metastatic castrate-resistant disease=
 +
==Sipuleucel-T (Provenge)==
 +
===Regimen===
 +
*[[Sipuleucel-T (Provenge)]]: leukapheresis followed 3 days later with at least 50 million autologous CD54+ cells activated with PAP-GM-CSF, to be done on weeks 0, 2, and 4
 +
 
 +
Supportive medications:
 +
*Recommended: Acetaminophen (Tylenol) and an antihistamine PO 30 minutes before each dose of Sipuleucel-T (Provenge)
 +
 
 +
===References===
 +
# Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. [http://www.nejm.org/doi/full/10.1056/NEJMoa1001294 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20818862 PubMed]
 +
# Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011 Sep;186(3):877-81. Epub 2011 Jul 23. [http://www.sciencedirect.com/science/article/pii/S0022534711038511 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21788048 PubMed]
 +
# [http://www.dendreon.com/prescribing-information.pdf Sipuleucel-T (Provenge) package insert]
  
 
=Links=
 
=Links=

Revision as of 08:49, 5 May 2012

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


Androgen deprivation therapy (ADT) & radiation therapy

Adjuvant Goserelin (Zoladex) & RT

Regimen

  • Goserelin (Zoladex) 3.6 mg SC every 4 weeks, to start during the last week of radiation therapy and to continue indefinitely or until progression
  • Radiation therapy, 1.8-2 Gy per fraction, with an initial 44-46 Gy to the pelvis, then an additional boost to the prostate that resulted in a total dose of 65-70 Gy in definitive radiation patients; 60-65 Gy total dose for post-prostatectomy patients

References

  1. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90. link to original article contains verified protocol PubMed

Goserelin (Zoladex), Flutamide (Eulexin), RT

Regimen

  • Goserelin (Zoladex) 3.6 mg SC every 4 weeks, to start 2 months prior to radiation therapy and to continue at least through the end of radiation therapy
  • Flutamide (Eulexin) 250 mg PO three times per day, to start 2 months prior to radiation therapy and to continue at least through the end of radiation therapy
  • Radiation therapy is started 2 months after start of androgen deprivation therapy (ADT), 1.8-2 Gy per fraction, with an initial 44-46 Gy to the pelvis, then an additional conedown to the prostate that resulted in a total dose of 65-70 Gy
  • Long-term ADT may continue to be given for up to 24 months after the completion of radiation therapy

References

  1. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52. link to original article contains verified protocol PubMed
  2. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-91. Epub 2008 Jan 2. link to original article contains verified protocol PubMed
  3. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23;299(3):289-95. link to original article PubMed
  4. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. Epub 2008 Apr 14. link to original article contains verified protocol PubMed
  5. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18. link to original article contains verified protocol PubMed

Leuprolide (Lupron), Flutamide (Eulexin), RT

Regimen

  • Leuprolide (Lupron) 7.5 mg SC every 4 weeks x 4 months, to start 2 months prior to radiation therapy
  • Flutamide (Eulexin) 250 mg PO three times per day x 4 months, to start 2 months prior to radiation therapy
  • Radiation therapy is started 2 months after start of androgen deprivation therapy (ADT), 1.8-2 Gy per fraction, with an initial 44-46 Gy to the pelvis, then an additional conedown to the prostate that resulted in a total dose of 65-70 Gy

References

  1. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18. link to original article contains verified protocol PubMed

Hormonal therapy

Bicalutamide (Casodex)

Regimen

Not approved for monotherapy in the United States. See combination regimens with Goserelin (Zoladex) & Leuprolide (Lupron).

References

  1. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447-56. contains protocol PubMed
  2. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579-82. link to original article contains verified protocol PubMed

Degarelix (Firmagon)

Regimen

  • Degarelix (Firmagon) 240 mg (given as 2 x 120 mg injections) SC once as an initial dose
    • Then, starting 28 days later, Degarelix (Firmagon) 80-160 mg (80 mg is recommended dose in package insert) SC every 28 days

References

  1. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. link to original article contains verified protocol PubMed
  2. Degarelix (Firmagon) package insert
  3. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836-42. Epub 2009 Nov 20. link to original article contains verified protocol PubMed

Flutamide (Eulexin)

Regimen

Not approved for monotherapy in the United States. See combination regimens with Goserelin (Zoladex) & Leuprolide (Lupron).

References

  1. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119-29; discussion 129-30. contains protocol PubMed
  2. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 1997;32(4):391-5; discussion 395-6. contains protocol PubMed

Goserelin (Zoladex)

Regimen

References

  1. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502-8. PubMed
  2. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119-29; discussion 129-30. contains protocol PubMed
  3. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ, Kennealey GT. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995 Aug;46(2):220-6. link to original article contains verified protocol PubMed
  4. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579-82. link to original article contains verified protocol PubMed

Goserelin (Zoladex) & Bicalutamide (Casodex)

Regimen

References

  1. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. contains protocol PubMed
  2. Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. contains protocol PubMed

Goserelin (Zoladex) & Flutamide (Eulexin)

Regimen

References

  1. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119-29; discussion 129-30. contains protocol PubMed
  2. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. contains protocol PubMed
  3. Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. contains protocol PubMed

Leuprolide (Lupron)

Regimen

OR

Supportive medications (varies depending on reference):

References

  1. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996 Jul-Aug;18(4):647-57. link to original article contains verified protocol PubMed
  2. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. link to original article PubMed
  3. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. link to original article contains verified protocol PubMed
  4. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836-42. Epub 2009 Nov 20. link to original article contains verified protocol PubMed

Leuprolide (Lupron) & Bicalutamide (Casodex)

Regimen

References

  1. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. contains protocol PubMed
  2. Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. contains protocol PubMed

Leuprolide (Lupron) & Flutamide (Eulexin)

Regimen

References

  1. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. contains protocol PubMed
  2. Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. contains protocol PubMed

Nilutamide (Nilandron)

Regimen

Approved "for use in combination with surgical castration for the treatment of metastatic prostate cancer."

start the day of, or day after surgical castration/orchiectomy

References

  1. Janknegt RA. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Cancer. 1993 Dec 15;72(12 Suppl):3874-7. PubMed
  2. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol. 1997 Jul;158(1):160-3. PubMed
  3. de Reijke T, Derobert E; Anandron /Nilutamide Study Group. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol. 2002 Aug;42(2):139-46. link to original article contains verified protocol PubMed
  4. Nilutamide (Nilandron) package insert

Second-line hormonal therapy

Abiraterone (Zytiga)

Regimen

References

  1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. link to original article contains verified protocol PubMed

Ketoconazole (Nizoral) & Hydrocortisone

Regimen

References

  1. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15;22(6):1025-33. link to original article contains verified protocol PubMed

Ketoconazole (Nizoral), Hydrocortisone, Dutasteride (Avodart)

Regimen

References

  1. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15;15(22):7099-105. Epub 2009 Nov 3. link to original article contains verified protocol PubMed

Chemotherapy for metastatic castrate-resistant disease

Cabazitaxel (Jevtana)

Regimen

21-day cycles x up to 10 cycles

Supportive medications:

  • "Antihistamine, corticosteroid (dexamethasone 8 mg or equivalent), and histamine H2-antagonist (except cimetidine)" given at least 30 minutes before cabazitaxel

References

  1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. link to original article contains verified protocol PubMed

Docetaxel (Taxotere)

Regimen #1, Tannock, et al. 2004 & Berthold, et al. 2008

21-day cycles x up to 10 cycles

Supportive medications:

  • Dexamethasone (Decadron) 8 mg PO/IV given 12 hours, 3 hours, and 1 hour before docetaxel
  • Antiemetics "according to local practice"

Regimen #2, weekly schedule, Tannock, et al. 2004 & Berthold, et al. 2008

42-day cycles x up to 5 cycles

Supportive medications:

References

  1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. link to original article contains verified protocol PubMed
  2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242-5. link to original article contains verified protocol PubMed

Mitoxantrone (Novantrone)

Regimen

21-day cycles x up to 10 cycles

References

  1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. link to original article contains verified protocol PubMed
  2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242-5. link to original article contains verified protocol PubMed
  3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. link to original article contains verified protocol PubMed

Immunotherapy for metastatic castrate-resistant disease

Sipuleucel-T (Provenge)

Regimen

  • Sipuleucel-T (Provenge): leukapheresis followed 3 days later with at least 50 million autologous CD54+ cells activated with PAP-GM-CSF, to be done on weeks 0, 2, and 4

Supportive medications:

  • Recommended: Acetaminophen (Tylenol) and an antihistamine PO 30 minutes before each dose of Sipuleucel-T (Provenge)

References

  1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. link to original article contains verified protocol PubMed
  2. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011 Sep;186(3):877-81. Epub 2011 Jul 23. link to original article contains verified protocol PubMed
  3. Sipuleucel-T (Provenge) package insert

Links

Retrieved from "https://hemonc.org/w/index.php?title=Prostate_cancer&oldid=1311"